Ofir Deri, David Ovadia, Ella Huszti, Michael Peled, Milton Saute, Tammy Hod, Amir Onn, Lior Seluk, Nadav Furie, Inbal Shafran, Ronen Mass, Sumit Chatterji, Liran Levy
BACKGROUND: Interstitial lung diseases (ILD) unresponsive to medical therapy often require lung transplantation (LTx), which prolongs quality of life and survival. Ideal timing for referral for LTx remains challenging, with late referral associated with significant morbidity and mortality. Among other criteria, patients with ILD should be considered for LTx if forced vital capacity (FVC) is less than 80% or diffusion capacity for carbon monoxide (DLCO) is less than 40%. However, data on referral rates are lacking...
2024: Therapeutic Advances in Respiratory Disease